BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22:482-491. [PMID: 22209361 DOI: 10.1016/j.euroneuro.2011.11.008] [Cited by in Crossref: 97] [Cited by in F6Publishing: 71] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol 2016;30:13-22. [DOI: 10.1177/0269881115609072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 14.6] [Reference Citation Analysis]
2 Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 2014;37:19-31. [PMID: 24338044 DOI: 10.1007/s40264-013-0129-4] [Cited by in Crossref: 71] [Cited by in F6Publishing: 40] [Article Influence: 10.1] [Reference Citation Analysis]
3 Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 2014;15:2525-42. [PMID: 25224953 DOI: 10.1517/14656566.2014.960842] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
4 McIntyre RS, Loft H, Christensen MC. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. Neuropsychiatr Dis Treat 2021;17:575-85. [PMID: 33654400 DOI: 10.2147/NDT.S296451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zimmerman M, Multach M, Walsh E, Rosenstein LK, Gazarian D, Clark HL. Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity. CNS Drugs 2016;30:185-91. [PMID: 26818632 DOI: 10.1007/s40263-016-0314-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mahableshwarkar AR, Jacobsen PL, Chen Y, Simon JS. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract 2014;68:49-59. [DOI: 10.1111/ijcp.12328] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
7 Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29:138-149. [PMID: 24257717 DOI: 10.1097/yic.0000000000000018] [Cited by in Crossref: 102] [Cited by in F6Publishing: 28] [Article Influence: 14.6] [Reference Citation Analysis]
8 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 42] [Article Influence: 12.6] [Reference Citation Analysis]
10 Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacology & Therapeutics 2013;137:119-31. [DOI: 10.1016/j.pharmthera.2012.09.006] [Cited by in Crossref: 193] [Cited by in F6Publishing: 153] [Article Influence: 24.1] [Reference Citation Analysis]
11 Maciukiewicz M, Marshe VS, Tiwari AK, Fonseka TM, Freeman N, Rotzinger S, Foster JA, Kennedy JL, Kennedy SH, Müller DJ. Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder. Pharmacogenomics 2015;16:1919-29. [PMID: 26556688 DOI: 10.2217/pgs.15.136] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
12 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
13 Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr 2016;21:367-78. [PMID: 26575433 DOI: 10.1017/S1092852915000553] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
14 Leiser SC, Iglesias-Bregna D, Westrich L, Pehrson AL, Sanchez C. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. J Psychopharmacol 2015;29:1092-105. [PMID: 26174134 DOI: 10.1177/0269881115592347] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
15 Carta MG, Pala AN, Finco G, Musu M, Moro MF. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health 2015;11:144-9. [PMID: 25893002 DOI: 10.2174/1745017901511010144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Florea I, Danchenko N, Brignone M, Loft H, Rive B, Abetz-webb L. The Effect of Vortioxetine on Health-related Quality of Life in Patients With Major Depressive Disorder. Clinical Therapeutics 2015;37:2309-2323.e6. [DOI: 10.1016/j.clinthera.2015.08.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
17 Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med 2015;12:2036-48. [PMID: 26331383 DOI: 10.1111/jsm.12980] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
18 Jacobsen PL, Nomikos GG, Zhong W, Cutler AJ, Affinito J, Clayton A. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CNS Spectr 2020;25:50-63. [DOI: 10.1017/s1092852919000750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
19 Li G, Wang X, Ma D. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig 2016;36:509-17. [DOI: 10.1007/s40261-016-0396-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
20 Leiser SC, Pehrson AL, Robichaud PJ, Sanchez C. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. Br J Pharmacol 2014;171:4255-72. [PMID: 24846338 DOI: 10.1111/bph.12782] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
21 Kyle PR, Lemming OM, Timmerby N, Søndergaard S, Andreasson K, Bech P. The Validity of the Different Versions of the Hamilton Depression Scale in Separating Remission Rates of Placebo and Antidepressants in Clinical Trials of Major Depression. J Clin Psychopharmacol 2016;36:453-6. [DOI: 10.1097/jcp.0000000000000557] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
22 Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology 2016;26:979-93. [DOI: 10.1016/j.euroneuro.2016.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 49] [Article Influence: 13.8] [Reference Citation Analysis]
23 Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14:276. [PMID: 25260373 DOI: 10.1186/s12888-014-0276-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
24 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
25 Baldwin DS, Nutt DJ. On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European Neuropsychopharmacology 2012;22:841-3. [DOI: 10.1016/j.euroneuro.2012.07.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014;10:1297-307. [PMID: 25075188 DOI: 10.2147/NDT.S41387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
27 Pearce EF, Murphy JA. Vortioxetine for the treatment of depression. Ann Pharmacother 2014;48:758-65. [PMID: 24676550 DOI: 10.1177/1060028014528305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
28 Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26:1408-1416. [PMID: 22495621 DOI: 10.1177/0269881112441866] [Cited by in Crossref: 74] [Cited by in F6Publishing: 56] [Article Influence: 8.2] [Reference Citation Analysis]
29 Meeker AS, Herink MC, Haxby DG, Hartung DM. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 2015;4:21. [PMID: 25874839 DOI: 10.1186/s13643-015-0001-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
30 Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012;10:CD006533. [PMID: 23076926 DOI: 10.1002/14651858.CD006533.pub2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
31 Kennedy SH. A review of antidepressant therapy in primary care: current practices and future directions. Prim Care Companion CNS Disord 2013;15:PCC. [PMID: 23930234 DOI: 10.4088/PCC.12r01420] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19:121-33. [PMID: 23903233 DOI: 10.1017/S1092852913000540] [Cited by in Crossref: 91] [Cited by in F6Publishing: 30] [Article Influence: 11.4] [Reference Citation Analysis]
33 Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-82. [PMID: 25087600 DOI: 10.1002/hup.2424] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 11.5] [Reference Citation Analysis]
34 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:60-82. [PMID: 24165478 DOI: 10.1111/ijcp.12350] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
36 Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol 2013;16:1433-42. [PMID: 23363735 DOI: 10.1017/S1461145712001605] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
37 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
38 Gibb A, Deeks ED. Vortioxetine: First Global Approval. Drugs 2014;74:135-45. [DOI: 10.1007/s40265-013-0161-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
39 Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2014;29:36-44. [PMID: 24169027 DOI: 10.1097/yic.0000000000000010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 18] [Article Influence: 5.6] [Reference Citation Analysis]
40 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
41 Christensen MC, Florea I, Loft H, McIntyre RS. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Affect Disord 2020;263:258-66. [PMID: 31818787 DOI: 10.1016/j.jad.2019.11.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
43 Beyer C, Cappetta K, Johnson JA, Bloch MH. Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants. Depress Anxiety 2017;34:1134-46. [DOI: 10.1002/da.22680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
44 Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. European Neuropsychopharmacology 2012;22:858-66. [DOI: 10.1016/j.euroneuro.2012.07.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
45 Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. Journal of Affective Disorders 2016;206:140-50. [DOI: 10.1016/j.jad.2016.07.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 6.6] [Reference Citation Analysis]
46 Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet 2018;57:673-86. [PMID: 29189941 DOI: 10.1007/s40262-017-0612-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 20.0] [Reference Citation Analysis]
47 Clayton AH, El Haddad S, Iluonakhamhe J, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opinion on Drug Safety 2014;13:1361-74. [DOI: 10.1517/14740338.2014.951324] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
48 Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S. A Review of Novel Antidepressants: A Guide for Clinicians. Cureus 2019;11:e4185. [PMID: 31106085 DOI: 10.7759/cureus.4185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
49 Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics 2015;145:43-57. [DOI: 10.1016/j.pharmthera.2014.07.001] [Cited by in Crossref: 245] [Cited by in F6Publishing: 179] [Article Influence: 40.8] [Reference Citation Analysis]
50 Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32:1086-97. [PMID: 30047820 DOI: 10.1177/0269881118788826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
51 Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr 2017;22:348-62. [PMID: 27869048 DOI: 10.1017/S1092852916000626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.2] [Reference Citation Analysis]
52 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2015;40:174-86. [PMID: 25350320 DOI: 10.1503/jpn.140120] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
53 Cosgrove L, Vannoy S, Mintzes B, Shaughnessy AF. Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation. Accountability in Research 2016;23:257-79. [DOI: 10.1080/08989621.2016.1153971] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
54 Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder: Vortioxetine for major depression. Psychiatry Clin Neurosci 2018;72:64-72. [DOI: 10.1111/pcn.12565] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
55 Citrome L. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 2016;196:225-33. [DOI: 10.1016/j.jad.2016.02.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
56 Tritschler L, Felice D, Colle R, Guilloux J, Corruble E, Gardier AM, David DJ. Vortioxetine for the treatment of major depressive disorder. Expert Review of Clinical Pharmacology 2014;7:731-45. [DOI: 10.1586/17512433.2014.950655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
57 Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological Management of Anxiety Disorders in the Elderly. Curr Treat Options Psychiatry 2017;4:33-46. [PMID: 28948135 DOI: 10.1007/s40501-017-0102-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
58 He H, Wang W, Lyu J, Zheng J, Guo L, An X, Fan Y, Ma X. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 2018;96:247-59. [DOI: 10.1016/j.jpsychires.2017.10.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
59 Parker G, Hadzi-pavlovic D. Do Hamilton depression scale items have the capacity to differentiate melancholic and non-melancholic depressive sub-types? Journal of Affective Disorders 2020;274:1022-7. [DOI: 10.1016/j.jad.2020.05.138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kennedy SH, Grouin JM, Cadour S, Robert V, Picarel-Blanchot F. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Hum Psychopharmacol 2018;33. [PMID: 29327372 DOI: 10.1002/hup.2646] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
61 Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. J Affect Disord 2016;190:357-61. [PMID: 26546771 DOI: 10.1016/j.jad.2015.10.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology 2017;27:773-81. [DOI: 10.1016/j.euroneuro.2017.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
63 Cappetta K, Beyer C, Johnson JA, Bloch MH. Meta-analysis: Risk of dry mouth with second generation antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2018;84:282-93. [DOI: 10.1016/j.pnpbp.2017.12.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
64 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res 2015;64:88-98. [PMID: 25851751 DOI: 10.1016/j.jpsychires.2015.02.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
65 Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri N. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT3 receptor antagonism. International Journal of Neuropsychopharmacology 2013;16:1115-27. [DOI: 10.1017/s1461145712001058] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
66 Holper L. Conditional power of antidepressant network meta-analysis. BMC Psychiatry 2021;21:129. [PMID: 33673822 DOI: 10.1186/s12888-021-03094-5] [Reference Citation Analysis]
67 Baldwin DS, Palazzo MC, Masdrakis VG. Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat. 2013;2013:256841. [PMID: 23431429 DOI: 10.1155/2013/256841] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
68 Clayton AH, Alkis AR, Parikh NB, Votta JG. Sexual Dysfunction Due to Psychotropic Medications. Psychiatr Clin North Am 2016;39:427-63. [PMID: 27514298 DOI: 10.1016/j.psc.2016.04.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
69 Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. J Sex Med 2019;16:1638-49. [PMID: 31405765 DOI: 10.1016/j.jsxm.2019.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
70 Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015;232:2061-70. [PMID: 25575488 DOI: 10.1007/s00213-014-3839-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
71 Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349-54. [PMID: 24570588 DOI: 10.2147/NDT.S39544] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]